BridgeBio Pharma (BBIO) Total Debt (2019 - 2025)
BridgeBio Pharma (BBIO) has disclosed Total Debt for 7 consecutive years, with $547.0 million as the latest value for Q4 2025.
- Quarterly Total Debt fell 25.97% to $547.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $547.0 million through Dec 2025, down 25.97% year-over-year, with the annual reading at $547.0 million for FY2025, 25.97% down from the prior year.
- Total Debt hit $547.0 million in Q4 2025 for BridgeBio Pharma, down from $740.4 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $740.4 million in Q3 2025 to a low of $94.4 million in Q1 2021.
- Historically, Total Debt has averaged $418.6 million across 5 years, with a median of $435.1 million in 2024.
- Biggest five-year swings in Total Debt: soared 359.83% in 2022 and later dropped 25.97% in 2025.
- Year by year, Total Debt stood at $430.8 million in 2021, then rose by 0.06% to $431.0 million in 2022, then rose by 3.59% to $446.4 million in 2023, then soared by 65.5% to $738.9 million in 2024, then decreased by 25.97% to $547.0 million in 2025.
- Business Quant data shows Total Debt for BBIO at $547.0 million in Q4 2025, $740.4 million in Q3 2025, and $738.9 million in Q4 2024.